248 related articles for article (PubMed ID: 29381731)
1. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
Luo H; Xu X; Ye M; Sheng B; Zhu X
PLoS One; 2018; 13(1):e0191972. PubMed ID: 29381731
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.
Zhou Y; Bian B; Yuan X; Xie G; Ma Y; Shen L
PLoS One; 2015; 10(6):e0130873. PubMed ID: 26098665
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis.
Petrelli F; Rea C; Parati MC; Borgonovo K; Ghilardi M; Dottorini L; Luciani A; Ghidini M; Ruatta F; Garrone O; Tomasello G
Anticancer Res; 2023 Oct; 43(10):4303-4313. PubMed ID: 37772569
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis.
Luo H; Li S; Zhao M; Sheng B; Zhu H; Zhu X
Oncotarget; 2017 May; 8(22):36845-36856. PubMed ID: 28415663
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
6. Survival differences between HER2-0 and HER2-low-expressing breast cancer - A meta-analysis of early breast cancer patients.
Yang C; Zhang X; Chen Y; Li P; Zhang J; Xu A; Huang N; Liang M; Chen Y; Wang K
Crit Rev Oncol Hematol; 2023 May; 185():103962. PubMed ID: 36921780
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
8. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
[TBL] [Abstract][Full Text] [Related]
9. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Wang L
J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of CXCR4 in ovarian cancer: a meta-analysis.
Liu CF; Liu SY; Min XY; Ji YY; Wang N; Liu D; Ma N; Li ZF; Li K
PLoS One; 2014; 9(3):e92629. PubMed ID: 24658065
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis.
Xia Y; Wei X; Gong H; Ni Y
BMC Womens Health; 2018 Dec; 18(1):199. PubMed ID: 30522488
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
Chung YW; Kim S; Hong JH; Lee JK; Lee NW; Lee YS; Song JY
J Gynecol Oncol; 2019 Sep; 30(5):e75. PubMed ID: 31328457
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
Qiao W; Liu H; Guo W; Li P; Deng M
Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
Piao J; Lim HJ; Lee M
Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
[TBL] [Abstract][Full Text] [Related]
16. Role of human epidermal growth factor receptor 2 as a prognostic factor for survival in esophageal carcinoma: evidence from 2872 subjects.
Wang WJ; Wu MJ; Chang J; Xie P; Lu ZQ; Ren JL
Minerva Med; 2016 Oct; 107(5):328-41. PubMed ID: 27309036
[TBL] [Abstract][Full Text] [Related]
17. Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis.
Zhang Q; Wang Q; Sun W; Gao F; Liu L; Cheng L; Li Z
Biomed Res Int; 2018; 2018():6124927. PubMed ID: 30596096
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis.
Wu Y; Li L; Zhang D; Ma F
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230471
[TBL] [Abstract][Full Text] [Related]
20. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
Huang C; Lin X; He J; Liu N
Gynecol Oncol; 2021 May; 161(2):613-620. PubMed ID: 33674144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
